Intel stock spikes after report of possible US government stake
LOS ANGELES - Kairos Pharma Ltd. (NYSE American: KAPA), a biopharmaceutical company specializing in oncology therapeutics with a market capitalization of $12.88 million, has announced a potentially significant advancement in the treatment of non-small cell lung cancer (NSCLC). InvestingPro data shows the company maintains a strong liquidity position with more cash than debt, though its shares have declined 63.85% over the past year. According to a peer-reviewed study published in Drug Resistance Updates, the company’s research has identified a mechanism that could overcome resistance to EGFR-targeted therapies in NSCLC. With a current ratio of 2.84, InvestingPro analysis indicates the company has sufficient liquid assets to fund its ongoing research initiatives.
The study, which focused on the role of CD105 (endoglin) in mediating resistance to osimertinib—a frontline treatment for EGFR-mutant NSCLC—found that upregulation of CD105 correlates with poor prognosis in patients. This resistance mechanism was notably counteracted in preclinical models by Kairos Pharma’s ENV105 (carotuximab), a CD105-neutralizing antibody. When combined with osimertinib, ENV105 reinstated susceptibility to EGFR inhibition, suggesting a new combination therapy strategy for overcoming drug resistance.
Neil Bhowmick, Ph.D., Chief Scientific Officer at Kairos Pharma, emphasized the significance of these findings, stating they represent a paradigm shift in addressing resistance to EGFR-targeted therapies in NSCLC. Dr. John Yu, CEO of Kairos Pharma, reinforced the potential of ENV105 to reverse drug resistance, a common challenge in cancer treatment, based on corroborating data from other cancer types.
Kairos Pharma is currently conducting clinical trials to evaluate the impact of ENV105 in EGFR-driven lung cancer patients. With the global NSCLC treatment market expected to reach $45 billion by 2030, the development of effective therapies against drug resistance remains a high priority. ENV105’s ability to enhance the effectiveness of EGFR-targeted therapy positions it as a promising asset in next-generation oncology treatments. According to InvestingPro analysis, while Kairos currently shows weak profitability metrics with a negative EBITDA of $1.83 million, analysts have set an optimistic price target of $9.00 per share, suggesting significant upside potential if clinical trials succeed.
This press release statement serves as the source for the information provided. It should be noted that forward-looking statements within the press release are not guarantees of future performance and are subject to risks and uncertainties. Kairos Pharma has cautioned readers not to place undue reliance on these statements.
In other recent news, Kairos Pharma Ltd. has reported significant developments across several areas. The company presented promising preclinical data at the American Association for Cancer Research Immuno-Oncology conference, showcasing compounds KROS 101 and KROS 401, which demonstrated potential in treating melanoma and glioblastoma. In terms of financial achievements, Kairos Pharma successfully closed a $3.5 million private investment in public equity (PIPE) transaction, issuing common and pre-funded warrants to accredited investors. The transaction was facilitated by Boustead Securities, LLC and D. Boral Capital LLC, acting as co-placement agents. Additionally, the company outlined its 2024 achievements and its goals for 2025, including ongoing clinical trials for its lead candidate, ENV105, targeting prostate and lung cancers. Kairos Pharma is also planning to continue its Phase 2 and Phase 1 trials in 2025, with initial safety data expected for prostate cancer in the first half of the year and for non-small cell lung cancer by year-end. The company has entered into a collaboration with PreCheck Health Services to develop a biomarker panel for identifying responsive patients for ENV105. Moreover, the City of Hope Cancer Center has joined the Phase 2 trial of ENV105 for castrate-resistant prostate cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.